Suppr超能文献

头孢噻呋制剂会使牛肠道内药物浓度、粪便大肠杆菌耐药性和微生物组产生差异。

Ceftiofur formulation differentially affects the intestinal drug concentration, resistance of fecal Escherichia coli, and the microbiome of steers.

机构信息

Department of Population Health and Pathobiology, College of Veterinary Medicine, NC State University, Raleigh, NC, United States of America.

Department of Food, Bioprocessing, and Nutrition Sciences, College of Agriculture and Life Sciences, NC State University, Raleigh, NC, United States of America.

出版信息

PLoS One. 2019 Oct 4;14(10):e0223378. doi: 10.1371/journal.pone.0223378. eCollection 2019.

Abstract

Antimicrobial drug concentrations in the gastrointestinal tract likely drive antimicrobial resistance in enteric bacteria. Our objective was to determine the concentration of ceftiofur and its metabolites in the gastrointestinal tract of steers treated with ceftiofur crystalline-free acid (CCFA) or ceftiofur hydrochloride (CHCL), determine the effect of these drugs on the minimum inhibitory concentration (MIC) of fecal Escherichia coli, and evaluate shifts in the microbiome. Steers were administered either a single dose (6.6 mg/kg) of CCFA or 2.2 mg/kg of CHCL every 24 hours for 3 days. Ceftiofur and its metabolites were measured in the plasma, interstitium, ileum and colon. The concentration and MIC of fecal E. coli and the fecal microbiota composition were assessed after treatment. The maximum concentration of ceftiofur was higher in all sampled locations of steers treated with CHCL. Measurable drug persisted longer in the intestine of CCFA-treated steers. There was a significant decrease in E. coli concentration (P = 0.002) within 24 hours that persisted for 2 weeks after CCFA treatment. In CHCL-treated steers, the mean MIC of ceftiofur in E. coli peaked at 48 hours (mean MIC = 20.45 ug/ml, 95% CI = 10.29-40.63 ug/ml), and in CCFA-treated steers, mean MIC peaked at 96 hours (mean MIC = 10.68 ug/ml, 95% CI = 5.47-20.85 ug/ml). Shifts in the microbiome of steers in both groups were due to reductions in Firmicutes and increases in Bacteroidetes. CCFA leads to prolonged, low intestinal drug concentrations, and is associated with decreased E. coli concentration, an increased MIC of ceftiofur in E. coli at specific time points, and shifts in the fecal microbiota. CHCL led to higher intestinal drug concentrations over a shorter duration. Effects on E. coli concentration and the microbiome were smaller in this group, but the increase in the MIC of ceftiofur in fecal E. coli was similar.

摘要

肠道内的抗菌药物浓度可能会导致肠道细菌产生抗药性。我们的目的是确定接受头孢噻呋游离酸(CCFA)或盐酸头孢噻呋(CHCL)治疗的牛的胃肠道内头孢噻呋及其代谢物的浓度,确定这些药物对粪便大肠杆菌最低抑菌浓度(MIC)的影响,并评估微生物组的变化。牛每 24 小时接受一次单剂量(6.6mg/kg)CCFA 或 2.2mg/kg 的 CHCL,共 3 天。在血浆、间质、回肠和结肠中测量头孢噻呋及其代谢物。在治疗后评估粪便大肠杆菌的浓度和 MIC 以及粪便微生物组组成。在接受 CHCL 治疗的牛的所有采样部位,头孢噻呋的最高浓度均较高。在接受 CCFA 治疗的牛的肠道中,可测量的药物持续时间更长。在 CCFA 治疗后 24 小时内,大肠杆菌浓度显著下降(P = 0.002),并持续了 2 周。在 CHCL 治疗的牛中,大肠杆菌中头孢噻呋的平均 MIC 在 48 小时达到峰值(平均 MIC = 20.45ug/ml,95%CI = 10.29-40.63ug/ml),而在 CCFA 治疗的牛中,平均 MIC 在 96 小时达到峰值(平均 MIC = 10.68ug/ml,95%CI = 5.47-20.85ug/ml)。两组牛的微生物组发生变化是由于厚壁菌门减少和拟杆菌门增加所致。CCFA 导致肠道内药物浓度持续时间延长且浓度较低,并与大肠杆菌浓度降低、特定时间点大肠杆菌中头孢噻呋的 MIC 升高以及粪便微生物群的变化有关。CHCL 导致肠道内药物浓度在较短时间内升高。该组对大肠杆菌浓度和微生物组的影响较小,但粪便大肠杆菌中头孢噻呋 MIC 的升高相似。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3543/6777789/b399f6c53367/pone.0223378.g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验